Ozempic-maker Novo open to upgrading US listing
Direct Source Verification:
This story is aggregated from Financial Times (ft.com). Full reporting rights and copyright belong to the primary publisher.
Boss Mike Doustdar says he sees ‘advantages’ in giving US investors direct access to Danish group’s stock
For complete coverage, context, and related multimedia, visit the original reporting by Financial Times via the source link below.
Original Source
https://www.ft.com/content/00d53ca3-725f-4fa8-b452-cef562a13514?syn-25a6b1a6=1
